{"abscess": 2.44, "administration site erythema": 7.64, "administration site reaction": 17.24, "adverse reaction": 3.71, "ankle fracture": 2.11, "asthma": 2.08, "atypical pneumonia": 10.62, "bacterial infection": 4.34, "blood immunoglobulin g decreased": 32.93, "bronchiectasis": 6.42, "bronchitis": 8.4, "cardiac operation": 5.15, "catheterisation cardiac": 5.91, "cellulitis": 5.31, "cholecystectomy": 7.07, "chronic inflammatory demyelinating polyradiculoneuropathy": 58.06, "chronic obstructive pulmonary disease": 2.91, "clostridium difficile infection": 3.82, "cystitis": 2.6, "diverticulitis": 3.76, "ear infection": 9.83, "escherichia infection": 5.97, "eye infection": 5.2, "fungal infection": 2.3, "gastric infection": 13.74, "gastroenteritis viral": 5.84, "head injury": 2.02, "hepatitis b": 11.17, "hepatitis b core antibody positive": 38.24, "hepatitis b surface antibody positive": 46.95, "hepatitis b virus test positive": 50.81, "hospitalisation": 3.77, "ill-defined disorder": 5.66, "immunoglobulins decreased": 30.02, "incorrect drug administration rate": 6.78, "infection": 5.4, "infusion site abscess": 385.93, "infusion site bruising": 371.73, "infusion site cellulitis": 233.48, "infusion site discharge": 311.57, "infusion site discolouration": 88.86, "infusion site erythema": 199.73, "infusion site extravasation": 11.61, "infusion site haemorrhage": 100.85, "infusion site induration": 167.96, "infusion site infection": 113.85, "infusion site inflammation": 57.37, "infusion site irritation": 93.87, "infusion site mass": 231.43, "infusion site nodule": 802.21, "infusion site oedema": 33.65, "infusion site pain": 98.82, "infusion site pruritus": 247.7, "infusion site rash": 125.11, "infusion site reaction": 64.15, "infusion site scab": 540.73, "infusion site swelling": 226.7, "infusion site ulcer": 430.65, "infusion site urticaria": 257.69, "infusion site vesicles": 125.73, "infusion site warmth": 218.75, "injection site bruising": 2.14, "injection site discharge": 19.16, "injection site discomfort": 2.86, "injection site erythema": 3.04, "injection site induration": 4.1, "injection site infection": 10.9, "injection site irritation": 10.72, "injection site mass": 4.54, "injection site necrosis": 13.53, "injection site nodule": 5.89, "injection site pruritus": 3.77, "injection site rash": 4.23, "injection site swelling": 2.1, "injection site ulcer": 22.87, "injection site urticaria": 6.08, "insurance issue": 26.15, "intestinal obstruction": 2.44, "kidney infection": 11.83, "knee arthroplasty": 3.24, "knee operation": 5.84, "laryngitis": 3.23, "limb operation": 7.57, "liquid product physical issue": 3.69, "lower respiratory tract infection": 3.78, "meningitis": 4.19, "meningitis aseptic": 38.0, "migraine": 2.54, "nephrolithiasis": 5.76, "no adverse event": 44.27, "osteomyelitis": 3.64, "pharyngitis streptococcal": 7.34, "pneumonia": 6.63, "product dose omission issue": 2.6, "product supply issue": 5.57, "product use complaint": 2.79, "productive cough": 3.29, "pseudomonas infection": 6.36, "recalled product administered": 31.6, "respiratory syncytial virus infection": 3.24, "respiratory tract congestion": 3.66, "respiratory tract infection": 23.6, "sinus congestion": 3.61, "sinus disorder": 6.11, "sinus operation": 53.52, "sinusitis": 19.82, "skin infection": 8.45, "skin mass": 2.72, "skin reaction": 2.16, "spinal operation": 6.53, "sputum discoloured": 5.31, "staphylococcal infection": 11.23, "stent placement": 4.94, "streptococcal infection": 10.18, "surgery": 4.75, "suspected transmission of an infectious agent via product": 69.58, "swelling": 2.03, "systemic lupus erythematosus": 2.74, "therapy cessation": 8.27, "therapy change": 10.8, "therapy interrupted": 17.66, "throat tightness": 2.21, "thrombosis": 2.63, "tooth abscess": 7.71, "tooth infection": 4.81, "unevaluable event": 6.48, "upper respiratory tract infection": 10.46, "urinary tract infection": 3.31, "urine output decreased": 7.03, "viral infection": 4.61, "weight fluctuation": 11.38, "wheezing": 2.05, "wound": 2.03, "wound infection": 4.16}